{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:27:35Z","timestamp":1778657255020,"version":"3.51.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["NRDIO 120187"],"award-info":[{"award-number":["NRDIO 120187"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["NRDIO 134791"],"award-info":[{"award-number":["NRDIO 134791"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Pruritus is a common excruciating symptom in systemic autoimmune diseases such as dermatomyositis (DM) but the pathogenesis is not fully understood. We intended to investigate the targeted expression analysis of candidate molecules involved in the development of pruritus in lesional vs. non-lesional skin samples of patients affected with active DM. We looked for correlations between the investigated pruriceptive signaling molecules, disease activity, and itching sensation of DM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Interleukins (IL-33 and IL-6), tumor necrosis factor \u03b1 (TNF-\u03b1), peroxisome proliferator-activated receptor \u03b3 (PPAR-\u03b3), and ion channels belonging to the transient receptor potential (TRP) family were analyzed. The expression of TNF-\u03b1, PPAR-\u03b3, IL-33, IL-6, and TRP channels in lesional DM skin was evaluated by RT-qPCR and immunohistochemistry and was compared with non-lesional DM skin samples. Pruritus, disease activity, and damage of DM were evaluated by the 5-D itch scale and Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), respectively. Statistical analysis was performed with IBM SPSS 28 software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 17 active DM patients participated in the study. We could show that the itching score was positively correlated with the CDASI activity score (Kendall's tau-b = 0.571; <jats:italic>p<\/jats:italic> = 0.003). TNF-\u03b1 gene expression was significantly higher in lesional DM skin than in non-lesional DM skin (<jats:italic>p<\/jats:italic> = 0.009) and differed in the subgroups of patients with different itch intensities (<jats:italic>p<\/jats:italic> = 0.038). The mRNA expression of lesional IL-6 correlated positively with 5-D itch and CDASI activity score (Kendall's tau-b = 0.585; <jats:italic>p<\/jats:italic> = 0.008 and 0.45; <jats:italic>p<\/jats:italic> = 0.013, respectively). TRPV4 expressions were positively correlated with CDASI damage score (Kendall's tau-b = 0.626; <jats:italic>p<\/jats:italic> &amp;lt; 0.001), but the mRNA expressions of the TRP family, PPAR-\u03b3, IL-6, and IL-33 were not different in lesional and non-lesional samples. Immunohistochemistry analysis did not find significant alterations in the expressions of TNF-\u03b1, PPAR-\u03b3, IL-6, and IL-33 in lesional and non-lesional regions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our results argue that cutaneous disease activity, TNF-\u03b1, and IL-6 might play a central role in DM-associated itch, while TRPV4 plays a central role in tissue regeneration.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1168359","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:45:00Z","timestamp":1683873900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Pruritogenic molecules in the skin of patients with dermatomyositis"],"prefix":"10.3389","volume":"10","author":[{"given":"Anett","family":"Vincze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Herczeg-Lisztes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor G\u00e1bor","family":"B\u00e9ldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Nagy-Vincze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"P\u00f3r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zsef","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Dank\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Bir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal\u00e1zs Istv\u00e1n","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Griger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br J Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","article-title":"Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life","volume":"54","author":"Hundley","year":"2006","journal-title":"J Am Acad Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1201\/b16573-3","article-title":"Epidemiology of Itch","volume":"29","author":"Weisshaar","year":"2014","journal-title":"Mech Treatment."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21144883","article-title":"Advances in understanding the initial steps of pruritoceptive itch: how the itch hits the switch","volume":"21","author":"Kahremany","year":"2020","journal-title":"Int J Mol Sci MDPI AG."},{"key":"B6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaci.2019.06.016","article-title":"Pruritus in allergy and immunology","volume":"144","author":"Yang","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/jdv.15973","article-title":"Neuroimmune interactions in chronic itch of atopic dermatitis","volume":"34","author":"Yosipovitch","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fphar.2022.745658","article-title":"Pruritus: a sensory symptom generated in cutaneous immuno-neuronal crosstalk","volume":"8","author":"Sz\u00f6llosi","year":"2022","journal-title":"Front Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s12264-017-0124-3","article-title":"TNF-\u03b1\/TNFR1 signaling is required for the full expression of acute and chronic itch in mice via peripheral and central mechanisms","volume":"34","author":"Miao","year":"2018","journal-title":"Neurosci Bull."},{"key":"B10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ejphar.2015.06.009","article-title":"The role of PPAR-gamma receptor in pruritus","volume":"762","author":"Ostadhadi","year":"2015","journal-title":"Eur J Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-212786","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/acr.20532","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitat","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2230.2004.01510.x","article-title":"Pruritus in adult dermatomyositis","volume":"29","author":"Shirani","year":"2004","journal-title":"Clin Exp Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s004010051165","article-title":"Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis","volume":"99","author":"Kuru","year":"2000","journal-title":"Acta Neuropathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0165-5728(95)00122-0","article-title":"Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls","volume":"63","author":"Lundberg","year":"1995","journal-title":"J Neuroimmunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"Amato","year":"2011","journal-title":"Ann Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2018","journal-title":"Autoimmun Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000114036","article-title":"Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate","volume":"59","author":"Hengstman","year":"2008","journal-title":"Eur Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/ijms23084301","article-title":"Pathophysiological mechanisms and treatment of dermatomyositis and immune mediated necrotizing myopathies: a focused review","volume":"23","author":"Kamperman","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Multiple Sclerosis J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.alit.2017.09.001","article-title":"A case of clinically amyopathic dermatomyositis that developed during anti-TNF-\u03b1 therapy for rheumatoid arthritis","volume":"67","author":"Takata","year":"2018","journal-title":"Allergol Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-02164-5","article-title":"Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients","volume":"22","author":"Campanilho-Marques","year":"2020","journal-title":"Arthritis Res Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/717808","article-title":"Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis","volume":"2013","author":"Yang","year":"2013","journal-title":"Clin Dev Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B29","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/ndt\/gfi204","article-title":"The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients","volume":"21","author":"Kimmel","year":"2006","journal-title":"Nephrol Dial Transplant."},{"key":"B30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/acr2.11493","article-title":"Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis","volume":"4","author":"Oddis","year":"2022","journal-title":"ACR Open Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1365-4632.2007.03273.x","article-title":"Thiazolidinediones in dermatology","volume":"46","author":"Boyd","year":"2007","journal-title":"Int J Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/00015550510030104","article-title":"Peroxisome proliferator-activated receptors and their relevance to dermatology","volume":"85","author":"Friedmann","year":"2005","journal-title":"Acta Derm Venereol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00128071-200809010-00002","article-title":"Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases","volume":"9","author":"Sertznig","year":"2008","journal-title":"Am J Clin Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0896-6273(00)80596-6","article-title":"hui, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation","volume":"21","author":"Jiang","year":"1998","journal-title":"Neuron."},{"key":"B35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1890\/1051-0761(2000)010(1057:LTCIVS)2.0.CO;2","article-title":"Long-term change in village-scale ecosystems in china using landscape and statistical methods","volume":"10","author":"Ellis EC Li","year":"2000","journal-title":"Ecol Appl."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/archderm.134.10.1304","article-title":"Treatment of psoriasis with troglitazone therapy","volume":"134","author":"Pershadsingh","year":"1998","journal-title":"Arch Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jaad.2006.10.033","article-title":"Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma","volume":"56","author":"Sepmeyer","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/archderm.136.5.609","article-title":"Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-\u03b3 inhibit keratinocyte proliferation","volume":"136","author":"Ellis","year":"2000","journal-title":"Arch Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.sder.2011.04.006","article-title":"Neuropathic itch","volume":"30","author":"Oaklander","year":"2011","journal-title":"Semin Cutan Med Surg."},{"key":"B41","doi-asserted-by":"publisher","first-page":"10252","DOI":"10.1074\/jbc.M116.716464","article-title":"Transient receptor potential vanilloid 4 ion channel functions as a pruriceptor in epidermal keratinocytes to evoke Histaminergic Itch","volume":"291","author":"Chen","year":"2016","journal-title":"J Biol Chem."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1168359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:45:03Z","timestamp":1683873903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1168359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":41,"alternative-id":["10.3389\/fmed.2023.1168359"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1168359","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"article-number":"1168359"}}